These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 17229962)

  • 1. AMG 531 for chronic ITP.
    Tauro S
    N Engl J Med; 2007 Jan; 356(3):307; author reply 308. PubMed ID: 17229962
    [No Abstract]   [Full Text] [Related]  

  • 2. AMG 531 for chronic ITP.
    Prasad K
    N Engl J Med; 2007 Jan; 356(3):307-8; author reply 308. PubMed ID: 17240535
    [No Abstract]   [Full Text] [Related]  

  • 3. The promise of thrombopoietins in the treatment of ITP.
    Kuter DJ
    Clin Adv Hematol Oncol; 2005 Jun; 3(6):464-6. PubMed ID: 16167023
    [No Abstract]   [Full Text] [Related]  

  • 4. Platelet production bolstered with romiplostim approval.
    Morrow T
    Manag Care; 2008 Oct; 17(10):49-50. PubMed ID: 18990926
    [No Abstract]   [Full Text] [Related]  

  • 5. The road to romiplostim approval and beyond.
    Lyman GH
    Oncology (Williston Park); 2009 Jul; 23(8):709-10, 715. PubMed ID: 19711586
    [No Abstract]   [Full Text] [Related]  

  • 6. Immune thrombocytopenic purpura--the changing therapeutic landscape.
    Bromberg ME
    N Engl J Med; 2006 Oct; 355(16):1643-5. PubMed ID: 17050888
    [No Abstract]   [Full Text] [Related]  

  • 7. AMG 531: an investigational thrombopoiesis-stimulating peptibody.
    Nichol JL
    Pediatr Blood Cancer; 2006 Oct; 47(5 Suppl):723-5. PubMed ID: 16933266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The REMS publication paradox.
    Andrews EB; Kaye JA; Van Bennekom C
    Oncology (Williston Park); 2009 Jul; 23(8):715-7. PubMed ID: 19711587
    [No Abstract]   [Full Text] [Related]  

  • 9. FDA approves thrombopoiesis-stimulating agent.
    Thompson CA
    Am J Health Syst Pharm; 2008 Oct; 65(19):1788. PubMed ID: 18796411
    [No Abstract]   [Full Text] [Related]  

  • 10. Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials.
    George JN; Mathias SD; Go RS; Guo M; Henry DH; Lyons R; Redner RL; Rice L; Schipperus MR
    Br J Haematol; 2009 Feb; 144(3):409-15. PubMed ID: 19016720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura.
    Kuter DJ
    Eur J Haematol Suppl; 2008 Feb; (69):9-18. PubMed ID: 18211568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increasing the platelet count in chronic ITP.
    Nurden AT; Nurden P
    Lancet; 2008 Feb; 371(9610):362-4. PubMed ID: 18242396
    [No Abstract]   [Full Text] [Related]  

  • 13. Novel thrombopoietic agents: preliminary activity, potential benefit.
    Bussel JB
    J Support Oncol; 2007 Apr; 5(4 Suppl 2):63-84. PubMed ID: 17550056
    [No Abstract]   [Full Text] [Related]  

  • 14. Quantifying the reduction in immunoglobulin use over time in patients with chronic immune thrombocytopenic purpura receiving romiplostim (AMG 531).
    Pullarkat VA; Gernsheimer TB; Wasser JS; Newland A; Guthrie TH; de Wolf JT; Stewart R; Berger D
    Am J Hematol; 2009 Aug; 84(8):538-40. PubMed ID: 19569197
    [No Abstract]   [Full Text] [Related]  

  • 15. Orphan disease gains second treatment option.
    Morrow T
    Manag Care; 2009 Jan; 18(1):47-9. PubMed ID: 19186672
    [No Abstract]   [Full Text] [Related]  

  • 16. A disease-specific measure of health-related quality of life in adults with chronic immune thrombocytopenic purpura: psychometric testing in an open-label clinical trial.
    Mathias SD; Bussel JB; George JN; McMillan R; Okano GJ; Nichol JL
    Clin Ther; 2007 May; 29(5):950-962. PubMed ID: 17697914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Children with ITP: looking beyond the platelet count.
    George JN
    Pediatr Blood Cancer; 2012 Mar; 58(3):323-4. PubMed ID: 21898785
    [No Abstract]   [Full Text] [Related]  

  • 18. [New therapeutic possibilities in chronic ITP in adults].
    Jönsson S; Olsson B; Wadenvik H
    Lakartidningen; 2009 May 20-Jun 2; 106(21-22):1476-9. PubMed ID: 19579436
    [No Abstract]   [Full Text] [Related]  

  • 19. Drug evaluation: AMG-531 for the treatment of thrombocytopenias.
    Rice L
    Curr Opin Investig Drugs; 2006 Sep; 7(9):834-41. PubMed ID: 17002262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura.
    Newland A; Caulier MT; Kappers-Klunne M; Schipperus MR; Lefrere F; Zwaginga JJ; Christal J; Chen CF; Nichol JL
    Br J Haematol; 2006 Nov; 135(4):547-53. PubMed ID: 17061981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.